[HTML][HTML] Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023
JT Solera, BG Árbol, A Mittal, V Hall, T Marinelli… - American Journal of …, 2024 - Elsevier
Data regarding coronavirus disease 2019 (COVID-19) outcomes in solid organ transplant
recipients (SOTr) across severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
recipients (SOTr) across severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant …
K Kawashiro, R Suzuki, T Nogimori, S Tsujino… - Scientific Reports, 2024 - nature.com
Abstract Although the mRNA SARS-CoV-2 vaccine has improved the mortality rate in the
general population, its efficacy against rapidly mutating virus strains, especially in kidney …
general population, its efficacy against rapidly mutating virus strains, especially in kidney …
SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study
DR Hijano, JA Ferrolino, EG Swift, CA Michaels… - Frontiers in …, 2023 - frontiersin.org
From 8 December 2021 to 26 January 2023, tixagevimab–cilgavimab (TC) was authorized
for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary …
for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary …
COVID-19 reinfection has better outcomes than the first infection in solid organ transplant recipients
Background. Solid organ transplant recipients face an increased risk of severe coronavirus
disease 2019 (COVID-19) and are vulnerable to repeat severe acute respiratory syndrome …
disease 2019 (COVID-19) and are vulnerable to repeat severe acute respiratory syndrome …
Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving …
VG Hall, THO Nguyen, LF Allen… - Open Forum …, 2023 - academic.oup.com
Background In-depth immunogenicity studies of tixagevimab-cilgavimab (TC) are lacking,
including following breakthrough coronavirus disease 2019 (COVID-19) in vaccinated …
including following breakthrough coronavirus disease 2019 (COVID-19) in vaccinated …
[HTML][HTML] Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric …
A Cona, A Tavelli, S Agrenzano, N Hafeez, G Scianna… - Microorganisms, 2024 - mdpi.com
Lung transplant recipients (LTRs) respond poorly to vaccination. SARS-CoV-2 pre-exposure
prophylaxis (PrEP) with tixagevimab/cilgavimab (TIX/CIL) reduces the incidence of infection …
prophylaxis (PrEP) with tixagevimab/cilgavimab (TIX/CIL) reduces the incidence of infection …
[HTML][HTML] Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study
Objective. We aimed to report the real-world use and outcomes over time in
immunocompromised individuals receiving tixagevimab/cilgavimab (T/C) pre-exposure …
immunocompromised individuals receiving tixagevimab/cilgavimab (T/C) pre-exposure …
Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab
R Aihara, K Umemura, Y Katada, S Nakagawa… - Journal of Infection and …, 2024 - Elsevier
Introduction Tixagevimab and cilgavimab (T/C) are neutralizing antibodies against severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be used to prevent SARS …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be used to prevent SARS …
COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study
N Nakamura, H Tsunemine, R Ikunari… - Leukemia & …, 2024 - Taylor & Francis
Abstract Knowledge of the SARS-CoV-2 antibody titers induced by tixagevimab–cilgavimab
in patients with hematologic diseases remains insufficient. Here, we performed a single …
in patients with hematologic diseases remains insufficient. Here, we performed a single …
[HTML][HTML] Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study
GM Assanto, M Totaro, R Poggiali… - … of Hematology and …, 2023 - ncbi.nlm.nih.gov
Methods We retrospectively collected data of patients affected by B-cell malignancies who
received TC MoAb (300 mg: dose 150+ 150 mg, the authorized dose for pre-exposure …
received TC MoAb (300 mg: dose 150+ 150 mg, the authorized dose for pre-exposure …